The fact that multiple Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders offloaded a considerable amount of ...

Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and ...

Alnylam Pharmaceuticals ALNY +1.01% Get Free Report is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish ...

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is among the best stocks added in a Growth Stock Portfolio.

Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 5 years ago, it would be worth $2,172.18 today based on a price of $322.83 for ALNY at the time of writing.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...